Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).

@article{Vibhagool2004TripleNT,
  title={Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-na{\"i}ve adults: results of a 48-week open-label, equivalence trial (CNA3014).},
  author={Asda Vibhagool and Pedro Cahn and Mauro Schechter and Fiona Mary Smaill and Luis Enrique Soto-Ram{\'i}rez and Giampiero Carosi and Maria Montroni and Cristina E Pharo and Jamie C Jordan and Nicola E Thomas and Gill Pearce},
  journal={Current medical research and opinion},
  year={2004},
  volume={20 7},
  pages={1103-14}
}
OBJECTIVE An equivalence (non-inferiority) trial comparing antiviral response, tolerability, and adherence with a triple nucleoside regimen containing abacavir 300 mg (ABC) plus a lamivudine 150-mg/zidovudine 300-mg combination tablet (COM) twice daily vs. a regimen containing the protease inhibitor indinavir (IDV) 800 mg three times daily plus COM twice daily (IDV/COM) in antiretroviral-naïve, HIV-infected patients. METHODS Adult patients with plasma HIV-1 RNA levels > or = 5000 copies/mL… CONTINUE READING
19 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 19 extracted citations

Similar Papers

Loading similar papers…